These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33112687)

  • 21. Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study.
    Li X; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Tong Y; Dong B; Wan L; Song X
    Front Immunol; 2023; 14():1252879. PubMed ID: 37954615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of Anti-thymocyte Globulin with Post-transplant Cyclophosphamide for GVHD Prophylaxis in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-analysis.
    Luo C; Huang X; Wu G; Huang Y; Ding Y; Huang Z; Song Q; Chen J; Li X; Xu S
    Transplant Cell Ther; 2024 Jul; ():. PubMed ID: 39084262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Modi D; Kondrat K; Kim S; Deol A; Ayash L; Ratanatharathorn V; Uberti JP
    Transplant Cell Ther; 2021 Sep; 27(9):760-767. PubMed ID: 34174469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia.
    Salas MQ; Chen S; Lam W; Pasic I; Gerbitz A; Michelis FV; Kim DDH; Al-Shaibani Z; Lipton JH; Mattsson J; Kumar R; Viswabandya A; Law AD
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1511-1519. PubMed ID: 32422253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia.
    Salas MQ; Prem S; Atenafu EG; Law AD; Lam W; Al-Shaibani Z; Loach D; Kim DDH; Michelis FV; Lipton JH; Kumar R; Mattsson J; Viswabandya A
    Eur J Haematol; 2019 Nov; 103(5):510-518. PubMed ID: 31449699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Tapering of Cyclosporine Is Feasible in Haploidentical Stem Cell Transplantation: A Single Center Experience.
    Yaman S; Başci S; Bozan E; Seçilmiş S; Candir BA; Yiğenoğlu TN; Çakar MK; Dal MS; Altuntaş F
    Clin Transplant; 2024 Jun; 38(6):e15376. PubMed ID: 39031699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
    Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
    Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia.
    Rocha V; Arcuri LJ; Seber A; Colturato V; Zecchin VG; Kuwahara C; Nichele S; Gouveia R; Fernandes JF; Macedo AV; Tavares R; Daudt L; De Souza MP; Darrigo-Jr LG; Villela NC; Mariano LCB; Ginani VC; Zanette A; Loth G; Gomes AA; Hamerschlak N; Flowers ME; Bonfim C;
    Bone Marrow Transplant; 2021 Dec; 56(12):3042-3048. PubMed ID: 34548627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
    Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
    Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
    Santoro N; Ruggeri A; Labopin M; Bacigalupo A; Ciceri F; Gülbaş Z; Huang H; Afanasyev B; Arcese W; Wu D; Koc Y; Tischer J; Santarone S; Giebel S; Mohty M; Nagler A
    J Hematol Oncol; 2017 May; 10(1):113. PubMed ID: 28558762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis.
    Gao WH; Zhu JY; Wang LN; Wan M; Wang L; Devillier R; Jiang JL; Blaise D; Hu J
    Front Med (Lausanne); 2023; 10():1140217. PubMed ID: 37064033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age.
    Baron F; Labopin M; Tischer J; Ciceri F; Raiola AM; Blaise D; Sica S; Vydra J; Fanin R; Stölzel F; Busca A; Diez-Martin JL; Koc Y; Nagler A; Mohty M
    Am J Hematol; 2022 Aug; 97(8):1065-1074. PubMed ID: 35696192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
    Otoukesh S; Elmariah H; Yang D; Clark MC; Siraj M; Ali H; Mogili K; Arslan S; Nishihori T; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Al Malki MM; Bejanyan N
    Transplant Cell Ther; 2022 Feb; 28(2):111.e1-111.e8. PubMed ID: 34844022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies.
    Alfaro Moya T; Salas MQ; Santos Carreira A; Atenafu EG; Law AD; Lam W; Pasic I; Kim DDH; Michelis FV; Novitzky Basso I; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Viswabandya A
    Bone Marrow Transplant; 2024 Apr; 59(4):534-540. PubMed ID: 38317015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival.
    Ali MM; Grønvold B; Remberger M; Abrahamsen IW; Myhre AE; Tjønnfjord GE; Fløisand Y; Gedde-Dahl T
    Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):598-605. PubMed ID: 34158268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
    Doppelhammer M; Fraccaroli A; Prevalsek D; Bücklein V; Häbe S; Schulz C; Hubmann M; Hausmann A; Claus R; Rank A; Schmid C; Tischer J
    Ann Hematol; 2019 Mar; 98(3):753-762. PubMed ID: 30617644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors.
    George B; Pn N; Devasia AJ; Kulkarni U; Korula A; Lakshmi KM; Abraham A; Srivastava A; Mathews V
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):494-500. PubMed ID: 29100905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO
    Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.